Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 10/20 | 0.52 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27756146 | 0.87 | KMT2A (0.58) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL18338361 | 0.85 | LMNA (0.65) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL1906943 | 0.85 | KMT2A (0.60) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL28765145 | 0.84 | KMT2A (0.55) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL325874 | 0.84 | KMT2A (0.51) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL12682657 | 0.83 | NPC1 (1.00) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL19659478 | 0.83 | HDAC1 (0.56) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL2485700 | 0.82 | HDAC1 (0.58) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL18377474 | 0.82 | HDAC1 (0.62) | KMT2ANPC1RAB9AMEN1HDAC1 | |
| SCHEMBL18338470 | 0.81 | HDAC1 (0.57) | KMT2ANPC1RAB9AMEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| CN-101528687-A | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same | KOREA RES INST CHEM TECH (KR) | 2009-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | KMT2A 3390/4885NPC1 541/4885RAB9A 979/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | KMT2A 3390/4885NPC1 541/4885RAB9A 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.